Sacubitril
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Cardiac & Hypertension treatment.
🧴 Clinical Application
Take orally twice daily with water, with or without food. When switching from an ACE inhibitor, a mandatory 36-hour washout period is required before starting sacubitril/valsartan to avoid fatal angioedema. Follow cardiologist's uptitration schedule.
⚠️ Side Effects
Common: Hypotension, hyperkalemia, cough, dizziness, elevated serum creatinine. Rare/Severe: Boxed warning: Fetal toxicity in pregnancy; severe angioedema (life-threatening airway obstruction), and acute renal failure.
🛡️ Safety Warnings
Black box warning: Fetal toxicity; contraindicated in pregnancy. Absolute contraindication with concurrent ACE inhibitors or within 36 hours of the last ACE inhibitor dose due to high risk of fatal angioedema. Contraindicated in history of angioedema. Regularly monitor serum potassium and renal function.
Jan Aushadhi Products containing Sacubitril
Found 3 generic formulation(s) containing this active ingredient.
Sacubitril 24mg + Valsartan 26mg Tablets
Sacubitril and Valsartan is a first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI) on the WHO Model List of Essential Medicines. Sacubitril is a prodrug whose active metabolite LBQ657 inhibits neprilysin (neutral endopeptidase), preventing the breakdown of endogenous natriuretic peptides (ANP, BNP, CNP) and promoting vasodilation, natriuresis, diuresis, and anti-remodeling, while valsartan selectively blocks the AT1 receptor, countering neprilysin-induced angiotensin II accumulation. Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA II-IV and reduced ejection fraction).
Sacubitril 49mg + Valsartan 51mg Tablets
Sacubitril and Valsartan is a first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI) on the WHO Model List of Essential Medicines. Sacubitril is a prodrug whose active metabolite LBQ657 inhibits neprilysin (neutral endopeptidase), preventing the breakdown of endogenous natriuretic peptides (ANP, BNP, CNP) and promoting vasodilation, natriuresis, diuresis, and anti-remodeling, while valsartan selectively blocks the AT1 receptor, countering neprilysin-induced angiotensin II accumulation. Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA II-IV and reduced ejection fraction).
Sacubitril 97mg + Valsartan 103mg Tablets
Sacubitril and Valsartan is a first-in-class Angiotensin Receptor-Neprilysin Inhibitor (ARNI) on the WHO Model List of Essential Medicines. Sacubitril is a prodrug whose active metabolite LBQ657 inhibits neprilysin (neutral endopeptidase), preventing the breakdown of endogenous natriuretic peptides (ANP, BNP, CNP) and promoting vasodilation, natriuresis, diuresis, and anti-remodeling, while valsartan selectively blocks the AT1 receptor, countering neprilysin-induced angiotensin II accumulation. Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure (NYHA II-IV and reduced ejection fraction).
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Sacubitril.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Sacubitril 24mg + Valsartan 26mg Tablets | 10's | ₹67.50 | VYMADA, CIDMUS, SACURISE, ARNICOR, ONARNI | ₹253.56 | 73% Save |
| Sacubitril 49mg + Valsartan 51mg Tablets | 10's | ₹131.25 | VYMADA, CIDMUS, ARNICOR, SACURISE, ONARNI | ₹403.37 | 67% Save |
| Sacubitril 97mg + Valsartan 103mg Tablets | 7’s | ₹212.81 | ARNICOR, CIDMUS, VYMADA | ₹553.57 | 62% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Sacubitril generics.